BACITRACIN ZINC-POLYMYXIN B SULFATE Drug Patent Profile

Which patents cover Bacitracin Zinc-polymyxin B Sulfate, and what generic alternatives are available?

Bacitracin Zinc-polymyxin B Sulfate is a drug marketed by Naska and is included in one NDA.

The generic ingredient in BACITRACIN ZINC-POLYMYXIN B SULFATE is bacitracin zinc; polymyxin b sulfate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the bacitracin zinc; polymyxin b sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bacitracin Zinc-polymyxin B Sulfate

A generic version of BACITRACIN ZINC-POLYMYXIN B SULFATE was approved as bacitracin zinc; polymyxin b sulfate by BAUSCH AND LOMB INC on January 26^th, 1995.

Summary for BACITRACIN ZINC-POLYMYXIN B SULFATE

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	1
DailyMed Link:	BACITRACIN ZINC-POLYMYXIN B SULFATE at DailyMed

Recent Clinical Trials for BACITRACIN ZINC-POLYMYXIN B SULFATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Glaxo Wellcome	N/A
National Institute of Allergy and Infectious Diseases (NIAID)	N/A

See all BACITRACIN ZINC-POLYMYXIN B SULFATE clinical trials

US Patents and Regulatory Information for BACITRACIN ZINC-POLYMYXIN B SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Naska	BACITRACIN ZINC-POLYMYXIN B SULFATE	bacitracin zinc; polymyxin b sulfate	OINTMENT;TOPICAL	062849-001	Nov 13, 1987		DISCN	No	No

Bacitracin Zinc-Polymyxin B Sulfate Market Dynamics, Patent Status, and Financial Trajectory

Last updated: July 31, 2026

Bacitracin zinc-polymyxin B sulfate is a mature topical antibiotic combination with limited patent protection, extensive generic availability, and low drug-level revenue transparency. Its market is divided between ophthalmic ointments, prescription dermatologic products, and over-the-counter first-aid preparations. Commercial growth is constrained by low prices, generic substitution, antimicrobial-stewardship concerns, allergic-contact dermatitis, and competition from non-antibiotic wound-care products.

The combination has no meaningful remaining regulatory exclusivity in the United States. Commercial value rests on manufacturing scale, retail distribution, brand recognition, ophthalmic quality controls, and customer access rather than on patent barriers.

What products contain bacitracin zinc and polymyxin B sulfate?

Bacitracin zinc-polymyxin B sulfate products combine two topical antibiotics:

Component	Pharmacologic role	Typical use
Bacitracin zinc	Inhibits bacterial cell-wall synthesis	Susceptible gram-positive skin and ocular pathogens
Polymyxin B sulfate	Disrupts bacterial cell membranes	Primarily susceptible gram-negative organisms

The combination is sold in several dosage forms:

• Ophthalmic ointment, generally containing bacitracin zinc and polymyxin B sulfate.
• Dermatologic ointment for minor cuts, abrasions, and burns.
• Prescription topical products that may combine the two antibiotics with neomycin or hydrocortisone.
• Branded and private-label first-aid products.

The ophthalmic combination is used for superficial bacterial infections of the eye and eyelid. Product labels typically limit treatment to short courses and warn against prolonged use, contamination of the applicator tip, and use in viral or fungal infections (DailyMed, 2024a; DailyMed, 2024b).

What is the FDA regulatory status of bacitracin zinc-polymyxin B sulfate?

The FDA regulates the combination through multiple product pathways rather than a single unified approval category.

Prescription ophthalmic products

Prescription ophthalmic ointments containing bacitracin zinc and polymyxin B sulfate are approved or marketed as abbreviated new drug application products. Generic versions commonly reference an established listed drug and compete through ANDA approval.

The product category has low clinical differentiation. Most approved ointments use the same active ingredients, comparable concentrations, and similar ophthalmic dosage forms. Competition therefore focuses on approval timing, manufacturing reliability, packaging, wholesaler contracts, and pharmacy reimbursement.

Over-the-counter first-aid products

Bacitracin and polymyxin B are recognized active ingredients for certain topical first-aid uses under the FDA’s OTC topical antimicrobial framework. OTC products must comply with applicable monograph conditions, including active-ingredient eligibility, concentrations, labeling, indications, warnings, and directions (FDA, 2020).

The OTC segment includes products sold under national brands, retailer brands, hospital brands, and generic labels. Some products use bacitracin alone, polymyxin B alone, or triple-antibiotic combinations rather than the two-ingredient formulation.

Orange Book status

The FDA Orange Book lists approved prescription drug products and therapeutic-equivalence information. Bacitracin zinc-polymyxin B sulfate ophthalmic ointments are generally represented by multiple approved generic products rather than by an active innovator product with enforceable market exclusivity (FDA, 2024a).

The Orange Book is less relevant to OTC-only products. OTC monograph products do not depend on an Orange Book-listed patent estate in the same way as a patented prescription product.

When does bacitracin zinc-polymyxin B sulfate lose exclusivity?

Bacitracin zinc-polymyxin B sulfate has already lost practical exclusivity.

Exclusivity category	Current position
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No material current protection
Prescription drug patent exclusivity	No meaningful active composition-of-matter barrier
OTC monograph protection	Product eligibility is governed by monograph compliance, not exclusivity
Generic substitution	Broadly available for prescription products
Biosimilar exclusivity	Not applicable

The active ingredients were discovered and commercialized decades ago. Any original composition, use, or formulation patents would have expired long before the current market period. Modern patents, if any, would need to cover a specific formulation, package, device, manufacturing process, or new use. Those claims would not normally prevent ordinary generic ointment competition.

What patents protect bacitracin zinc-polymyxin B sulfate?

No central, commercially significant patent estate currently protects the active-ingredient combination in its conventional ophthalmic or dermatologic ointment form.

Composition patents

The basic combination is too old to retain enforceable composition-of-matter protection. Bacitracin and polymyxin B are established antibiotics with long commercial histories. A manufacturer cannot obtain a new composition patent merely by selling the known ingredients together in a conventional ointment.

Formulation patents

Potentially protectable subject matter includes:

• Preservative-free ophthalmic formulations.
• Improved ointment bases.
• Enhanced stability or reduced degradation.
• Single-dose tubes or unit-dose packaging.
• Novel delivery systems.
• Controlled-release topical systems.
• Reduced-irritation formulations.
• Combination products with a genuinely new active ingredient or clinical use.

These patents would protect a particular product design, not the entire bacitracin-polymyxin market. A generic manufacturer could often design around them by using a different base, package, concentration, or manufacturing method.

Method-of-use patents

Method-of-use claims could cover a narrowly defined infection, dosing schedule, patient population, or procedure-related application. Such claims have limited commercial effect where the drug is already broadly used for established topical infections and where generic products carry broad labeling.

Manufacturing patents

Potential manufacturing protection could involve:

• Purification of polymyxin B components.
• Control of bacitracin potency.
• Sterile ophthalmic filling.
• Ointment homogenization.
• Stability improvement.
• Reduced particulate burden.

Manufacturing know-how can create quality and supply advantages without creating legal exclusivity. The practical barrier is compliance with current good manufacturing practice rather than patent enforcement.

How many patents cover bacitracin zinc-polymyxin B sulfate?

There is no commercially relevant patent count comparable to the estate surrounding a modern branded drug. Patent databases may return historical patents, formulation patents, process patents, and patents that mention bacitracin or polymyxin B without covering the marketed combination.

A useful competitive distinction is:

Patent category	Commercial relevance
Expired ingredient patents	None for current exclusivity
Expired combination patents	None for current exclusivity
Narrow formulation patents	Product-specific and potentially design-aroundable
Process patents	May affect manufacturing cost or quality
Device and packaging patents	May affect a particular presentation
Active Orange Book-listed patents	No broad blocking estate identified for the conventional combination

Patent-count analysis should therefore exclude expired documents, abandoned applications, patents that merely list the ingredients, and patents unrelated to the commercial dosage form.

What is the competitive landscape for bacitracin zinc-polymyxin B sulfate?

Competition is fragmented and largely price-based.

Direct competitors

Direct competitors include:

• Generic bacitracin-polymyxin ophthalmic ointments.
• Bacitracin-only ophthalmic products.
• Polymyxin B-based ophthalmic products.
• Triple-antibiotic ophthalmic ointments containing neomycin.
• Branded ophthalmic ointments.
• Retail first-aid ointments containing bacitracin, polymyxin B, or neomycin.

Therapeutic substitutes

The combination also competes with:

• Fluoroquinolone ophthalmic drops.
• Aminoglycoside ophthalmic products.
• Macrolide ophthalmic ointments.
• Oral or topical antibiotics selected according to culture results.
• Non-antibiotic wound-care products.
• Petrolatum-based ointments for uncomplicated minor wounds.

Drops can be preferred for some ocular indications because they are easier to administer and less visually occlusive than ointments. Ointments retain value where prolonged ocular contact, overnight treatment, or lubrication is clinically useful.

Manufacturer economics

Manufacturers compete through:

• Low-cost active pharmaceutical ingredient sourcing.
• Sterile manufacturing capacity.
• Consistent potency and microbiological quality.
• Reliable tube and carton supply.
• Pharmacy benefit-manager access.
• Retailer private-label contracts.
• Short lead times during shortages.

The market can experience supply volatility despite low clinical differentiation because the number of qualified sterile manufacturers is smaller than the number of nominal product labels.

What generic entry risks exist for bacitracin zinc-polymyxin B sulfate?

Generic entry risk is high because the market has no meaningful formulation or regulatory barrier for a conventional ointment.

A generic entrant generally faces:

1. ANDA development and FDA review for a prescription product.
2. Demonstration of pharmaceutical equivalence.
3. Establishment of bioequivalence or the applicable product-specific standard.
4. Sterile manufacturing validation for ophthalmic products.
5. Container-closure and stability testing.
6. Commercial-scale quality control.
7. Wholesaler and pharmacy contracting.

The largest barriers are operational rather than legal. Ophthalmic ointments require reliable sterile filling, validated equipment, stable raw materials, and control of particulate contamination. A manufacturer that fails to maintain supply can lose contracts quickly because buyers can switch to another approved generic.

Are there Paragraph IV challenges or patent litigation?

Paragraph IV risk is limited because the conventional product lacks a valuable active patent estate.

An ANDA applicant may file a Paragraph IV certification if it determines that an Orange Book-listed patent is invalid, unenforceable, or not infringed. In this product category, litigation would likely concern a narrow formulation, packaging, or use patent rather than the bacitracin-polymyxin combination itself.

The commercial exposure from such litigation is modest compared with a branded small-molecule product with billions of dollars in annual sales. The likely outcome of a successful challenge would be preservation of generic entry rather than disruption of a high-value franchise.

Publicly visible litigation involving topical antibiotic products is more likely to concern:

• Product liability.
• Advertising claims.
• False or misleading labeling.
• Manufacturing quality.
• OTC monograph compliance.
• Patent disputes involving a specific branded formulation.

No major current Paragraph IV case is known to create a market-wide block on conventional bacitracin zinc-polymyxin B sulfate products.

What formulation patents protect bacitracin zinc-polymyxin B sulfate?

The strongest potential formulation claims would target differentiated products rather than ordinary ointments.

Preservative-free ophthalmic products

Preservative-free presentations can address tolerability concerns and may support use in patients requiring repeated administration. Protection would depend on the specific formulation, package, and stability profile.

Improved ointment vehicles

A novel vehicle could improve spreadability, residence time, comfort, drug release, or product stability. A patent would need claims that distinguish the vehicle from conventional petrolatum or mineral-oil bases.

Unit-dose delivery

Single-use tubes or sterile unit-dose systems can reduce contamination risk. Packaging patents may create a limited barrier, but competing manufacturers can often use alternate container designs.

Combination products

A product that combines bacitracin-polymyxin with another active ingredient or a new delivery technology may obtain patents or regulatory exclusivity for the new component. The established two-antibiotic combination would remain available outside the protected design.

How does the financial trajectory compare with modern branded antibiotics?

Bacitracin zinc-polymyxin B sulfate is a mature, low-revenue-per-unit product. Its financial profile differs from newer antibiotics that depend on patent-protected pricing.

Metric	Bacitracin-polymyxin ointment	Modern branded antibiotic
Pricing power	Low	Potentially high during exclusivity
Generic competition	Extensive	Delayed until patent expiry
Revenue disclosure	Usually not product-specific	Often reported by brand
Gross margin	Dependent on manufacturing scale	Supported by branded pricing
R&D requirement	Low for standard products	High
Regulatory risk	Manufacturing and labeling	Clinical, patent, and reimbursement
Growth driver	Volume, distribution, private label	New indications and price
Financial risk	Supply interruption and commoditization	Patent cliffs and clinical failure

Drug-level revenue for bacitracin zinc-polymyxin B sulfate is generally not separately disclosed by manufacturers. Companies report broader categories such as consumer health, ophthalmology, hospital products, or generic pharmaceuticals. Sales of brands that contain bacitracin or polymyxin B are also difficult to isolate because retailers sell multiple formulations under the same brand family.

The expected financial trajectory is therefore:

• Stable to declining unit prices.
• Flat or modestly declining demand for conventional first-aid use.
• Continued demand in selected ophthalmic and hospital settings.
• Margin pressure from generic substitution.
• Periodic revenue increases during competitor shortages.
• Greater commercial value for reliable supply than for incremental clinical differentiation.

What regulatory and clinical factors affect future demand?

Antimicrobial stewardship limits unnecessary use of topical antibiotics. For minor wounds, clinicians and consumers may prefer plain petrolatum or other non-antibiotic wound-care products when infection is absent. Repeated exposure can cause allergic contact dermatitis, particularly with bacitracin. The American Contact Dermatitis Society named bacitracin a Contact Allergen of the Year, reflecting its recognized role in sensitization and dermatitis (Jacob et al., 2011).

The clinical market remains viable because topical antibiotics retain uses in selected ocular infections, post-procedural care, and infected minor skin injuries. Demand is unlikely to disappear, but the product is unlikely to generate branded-drug growth without a new delivery system, new indication, or differentiated safety profile.

What licensing deals affect bacitracin zinc-polymyxin B sulfate?

No major licensing transaction is central to the conventional combination’s market value. The products are generally manufactured and distributed through generic, consumer-health, hospital, or private-label arrangements.

Commercial agreements are more likely to involve:

• Contract manufacturing.
• Authorized generic distribution.
• Retail private-label supply.
• Hospital purchasing contracts.
• Brand licensing.
• Regional distribution rights.

These agreements can shift market share without changing the underlying patent position. A licensee’s advantage is usually channel access or manufacturing capacity rather than exclusive rights to the active ingredients.

What geographic markets offer the strongest opportunity?

The United States has a large established market but limited pricing power. Europe and other regulated markets also have generic topical antibiotic competition, although product classification, prescription status, reimbursement, and antimicrobial-use policies differ by country.

Emerging markets may offer volume growth through retail access and lower-cost products. The principal risks are:

• Local registration requirements.
• Counterfeit or substandard products.
• Limited sterile manufacturing capacity.
• Price controls.
• Distribution fragmentation.
• Different treatment guidelines.
• Local restrictions on nonprescription antibiotic sales.

Geographic expansion is therefore a registration and distribution strategy, not a patent-exclusivity strategy.

Key Takeaways

• Bacitracin zinc-polymyxin B sulfate is a mature topical antibiotic combination with no meaningful current composition-of-matter exclusivity.
• Prescription ophthalmic products compete through ANDA approval, manufacturing quality, supply reliability, and price.
• OTC products operate mainly under FDA monograph conditions and are outside the conventional Orange Book patent model.
• Patent risk is limited to narrow formulations, packages, delivery systems, methods of use, or manufacturing processes.
• Paragraph IV and patent litigation are unlikely to create a market-wide entry barrier.
• Biosimilar analysis is not relevant because the product contains small-molecule and peptide antibiotic ingredients, not a biologic.
• Revenue is generally not reported at the combination level.
• The financial trajectory is mature and low-growth, with volume stability offset by price erosion and stewardship concerns.
• Sterile ophthalmic manufacturing and dependable supply are stronger barriers than patents.
• The best commercial opportunities are differentiated formulations, preservative-free delivery, private-label supply, and shortage-resilient manufacturing.

FAQs

Is bacitracin zinc-polymyxin B sulfate still under patent protection?

The conventional combination is not protected by an active broad composition patent. Narrow patents may apply to particular formulations, delivery devices, packages, or manufacturing processes.

Is bacitracin zinc-polymyxin B sulfate an antibiotic or a biologic?

It is an antibiotic combination. Bacitracin is a peptide antibiotic, and polymyxin B is a cyclic peptide antibiotic, but the product is not regulated as a biologic comparable to a monoclonal antibody or therapeutic protein.

Can a generic manufacturer launch bacitracin-polymyxin ophthalmic ointment?

Yes, subject to FDA approval, applicable patent certifications, sterile manufacturing requirements, product-specific testing, and commercial supply capacity.

Why do bacitracin-polymyxin products sometimes become difficult to obtain?

Shortages can result from manufacturing interruptions, sterile-facility constraints, raw-material problems, quality investigations, packaging shortages, or a limited number of qualified suppliers.

Does bacitracin-polymyxin ointment have higher commercial value than bacitracin alone?

The combination can provide broader antibacterial coverage than either ingredient alone, but its commercial value is limited by low pricing, generic competition, alternative antibiotic products, and non-antibiotic wound-care substitutes.

References

1. DailyMed. (2024a). Bacitracin zinc and polymyxin B sulfate ophthalmic ointment: Prescribing information. U.S. National Library of Medicine.

2. DailyMed. (2024b). Bacitracin zinc and polymyxin B sulfate ointment: Drug labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2020). Safety and effectiveness of health care antiseptics; topical antimicrobial drug products for over-the-counter human use. Federal Register.

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. Jacob, S. E., Amini, S., McGowan, P., Nedorost, S., & Tosti, A. (2011). Bacitracin: A significant contact allergen in the United States. Dermatitis, 22(5), 246-250.